{"text": "Merck previously predicted a range for 2020 of 4.45 billion to 4.85 billion euros, up from 4.39 billion a year earlier.Merck said it won additional business related to the COVID-19 effort but also saw a strong recovery of the business following the closures of academic laboratories in the first half of 2020 due to the pandemic.In the third quarter, adjusted core profit for the group, or earnings before interest, taxes, depreciation and amortisation (EBITDA), jumped more than 50% to 1.7 billion euros, beating the average estimate of 1.6 billion in an analyst poll posted on its website.Earnings at its life science tools division, which supplies gear and chemicals for biotech labs, rose a better-then-expected 19% to 630 million euros."}